There are numerous studies available that correlated LCN2 with obesity, insulin resistance and diabetes (Yan et al., 2007; Law et al., 2010) rendering LCN2 as a possible biomarker for assessment of FLD. This evidence concerns the gene LCN2 and diabetes mellitus.